Renovorx Stock Alpha and Beta Analysis

RNXT Stock  USD 1.29  0.08  6.61%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as RenovoRx. It also helps investors analyze the systematic and unsystematic risks associated with investing in RenovoRx over a specified time horizon. Remember, high RenovoRx's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to RenovoRx's market risk premium analysis include:
Beta
0.64
Alpha
0.46
Risk
4.91
Sharpe Ratio
0.12
Expected Return
0.58
Please note that although RenovoRx alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, RenovoRx did 0.46  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of RenovoRx stock's relative risk over its benchmark. RenovoRx has a beta of 0.64  . As returns on the market increase, RenovoRx's returns are expected to increase less than the market. However, during the bear market, the loss of holding RenovoRx is expected to be smaller as well. Enterprise Value is likely to gain to about 44.5 M in 2024, despite the fact that Book Value Per Share is likely to grow to (0.28).

Enterprise Value

44.51 Million

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out RenovoRx Backtesting, RenovoRx Valuation, RenovoRx Correlation, RenovoRx Hype Analysis, RenovoRx Volatility, RenovoRx History and analyze RenovoRx Performance.
For more information on how to buy RenovoRx Stock please use our How to Invest in RenovoRx guide.

RenovoRx Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. RenovoRx market risk premium is the additional return an investor will receive from holding RenovoRx long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in RenovoRx. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate RenovoRx's performance over market.
α0.46   β0.64

RenovoRx expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of RenovoRx's Buy-and-hold return. Our buy-and-hold chart shows how RenovoRx performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

RenovoRx Market Price Analysis

Market price analysis indicators help investors to evaluate how RenovoRx stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading RenovoRx shares will generate the highest return on investment. By understating and applying RenovoRx stock market price indicators, traders can identify RenovoRx position entry and exit signals to maximize returns.

RenovoRx Return and Market Media

The median price of RenovoRx for the period between Tue, Aug 27, 2024 and Mon, Nov 25, 2024 is 1.02 with a coefficient of variation of 6.57. The daily time series for the period is distributed with a sample standard deviation of 0.07, arithmetic mean of 1.04, and mean deviation of 0.05. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP for Targeted Treatment of Locally Advanced Pancreatic Cancer
09/19/2024
2
Acquisition by Spiegel Robert J. of 25099 shares of RenovoRx at 1.02 subject to Rule 16b-3
10/01/2024
3
Northwell Health Cancer Institute Launches Patient Enrollment in RenovoRxs Ongoing Pivotal ...
11/20/2024
4
Acquisition by Shaun Bagai of 40983 shares of RenovoRx at 1.22 subject to Rule 16b-3
11/22/2024

About RenovoRx Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including RenovoRx or other stocks. Alpha measures the amount that position in RenovoRx has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2022 2023 2024 (projected)
Current Ratio6.591.251.19
Net Debt To EBITDA0.650.10.0978

RenovoRx Upcoming Company Events

As portrayed in its financial statements, the presentation of RenovoRx's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, RenovoRx's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of RenovoRx's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of RenovoRx. Please utilize our Beneish M Score to check the likelihood of RenovoRx's management manipulating its earnings.
7th of March 2024
Upcoming Quarterly Report
View
20th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
7th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with RenovoRx

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for RenovoRx Stock Analysis

When running RenovoRx's price analysis, check to measure RenovoRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy RenovoRx is operating at the current time. Most of RenovoRx's value examination focuses on studying past and present price action to predict the probability of RenovoRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move RenovoRx's price. Additionally, you may evaluate how the addition of RenovoRx to your portfolios can decrease your overall portfolio volatility.